Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin in Overactive Bladder
NCT01486706Phase 3Completed
- Start
- Oct 2010
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gabapentin in overactive bladder syndrome (OAB) (3 arms). Primary endpoint: Improvement of symptom domain at 12 weeks. Started Oct 2010; status: completed.
02
Drugs
gabapentin
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT01486706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01486706.